Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a research note released on Thursday, MarketBeat reports. Wedbush currently has a $30.00 price objective on the stock. Wedbush also issued estimates for Arcus Biosciences’ FY2028 earnings at $1.87 EPS. Other equities analysts have also recently issued research reports about […]
Gilead stock downgraded at Truist (NASDAQ:GILD) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical.
Arcus Biosciences Announces New Employment Inducement Grants streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.